Microparticulate Drug Delivery Systems as an Adjunct to Cancer Treatment
- 1 January 1987
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Drug Delivery
- Vol. 4 (1) , 55-61
- https://doi.org/10.1089/cdd.1987.4.55
Abstract
In an attempt to improve the therapeutic ratio of cytotoxic drugs, which have steep dose-response curves, microparticulate drug delivery systems (MDDS) have been designed for regional administration. Introduction of antineoplastic drug containing microspheres, of appropriate size, into the arterial system of an organ harboring primary or metastatic tumor, will cause tumor infarction by an embolic effect and provide a slow release source of drug trapped within the tumor microvasculature. This review describes recent innovations in synthesis of MDDS and their potential clinical application.This publication has 33 references indexed in Scilit:
- Targeted Modulation of Acute InflammationScience, 1985
- Adriamycin‐loaded albumin microspheres: Preparation, in vivo distribution and release in the ratBiopharmaceutics & Drug Disposition, 1985
- Regional chemotherapy of colorectal cancer metastatic to the liverCancer, 1984
- Multivariate Analysis of a Personal Series of 247 Patients with Liver Metastases from Colorectal CancerAnnals of Surgery, 1984
- A Prospective Phase II Clinical Trial of Continuous FUDR Regional Chemotherapy for Colorectal Metastases to the LiverAnnals of Surgery, 1983
- Long-term intraarterial chemotherapy infusion of ambulatory head and neck cancer patientsJournal of Surgical Oncology, 1982
- Characterization, toxicity and therapeutic efficacy of adrïamycin encapsulated in liposomesEuropean Journal of Cancer and Clinical Oncology, 1982
- New Implantable Continuous Administration and Bolus Dose Intracarotid Drug Delivery System for the Treatment of Malignant GliomasNeurosurgery, 1982
- Adrenergic innervation of tumour blood vesselsCancer Letters, 1977